T h e transmissible spongiform encephalopathies include human diseases such as Creutzfeldt-Jakob disease (CJD) and kuru as well as animal diseases such as scrapie and bovine spongiform encephalopathy (BSE). T h e emergence of variant CJD, which is causally related to BSE, has generated much interest in the development of rapid and sensitive diagnostic tests for the pre-mortem diagnosis of CJD. In 1986 two proteins were detected in the cerebrospinal fluid (CSF) of patients with sporadic CJD. These proteins were later demonstrated to be members of the 14-3-3 family, and tests for the detection of C S F 14-3-3 were developed. A number of studies have shown that the detection of C S F 14-3-3 is an accurate test for sporadic CJD, although the results with variant CJD are less promising.
Introduction
Creutzfeldt-Jakob disease (C JD) belongs to a family of rare fatal neurodegenerative diseases known as transmissible spongiform encephalopathies, that also include animal diseases such as scrapie and bovine spongiform encephalopathy (BSE) . These diseases are characterized by neuropathological evidence of neuronal loss, astrocytosis and spongiform change. The brains of these patients also show deposition of a partially proteinase K-resistant isoform (PrP".) of a sialoglycoprotein called the host-encoded prion protein (PrP'). PrP" is coded for by the prion protein gene (PRNP) located on chromosome 20 and is expressed throughout the body but in particularly high levels in neuronal cells, where it is found as a glycosylphosphatidylinositol-anchored cell surface protein [l] . These diseases can be transmitted Key word: cerebrospinal fluid, encephalopathy, prion disease. Abbreviations used: CJD, Creutzfeldt-Jakob disease; spCJD, sporadic CJD; vCJD, variant CJD; CSF, cerebrospinal fluid; BSE, bovine spongiform encephalopathy ; PrP, host-encoded prion protein ; PrP", proteinase K-resistant prion protein; PRNP, prion protein gene; h-GH, human cadaveric pituitaryderived growth hormone. 'e-mail alison.green@ed.ac.uk to chimpanzees and other laboratory animals in brain tissue from infected patients by either intracerebral or peripheral inoculation, although much larger doses are required for peripheral transmission [2] . T h e transmissible agent has been shown to co-localize with PrPSc and is resistant to most agents that inactivate nucleic acid and viruses. For a review of transmissible spongiform encephalopathies see Johnson and Gibbs [3] .
T h e majority of cases of CJD (85010) A variant form of CJD (vCJD) was described in 1996, which affects younger patients and has a more prolonged clinical course when compared to spCJD [11, 12] . Subsequent evidence has provided strong support for the hypothesis that vCJD is causally linked to BSE [13, 14] . These patients tend to present with early and persistent psychiatric symptoms and definitive neurological features such as ataxia and cognitive impairment develop at a relatively late stage [15, 16] . 4-5 [19] . The 14-3-3 proteins are expressed in all eukaryotic cells [20] and are a group of multifunctional proteins that bind to and modulate the function of a wide array of cellular proteins; including kinases, phosphatases and transmembrane receptors. Through these interactions, 14-3-3 participates in the regulation of diverse biological processes, including neuronal development, cell growth control and cell cycling [19, 20] .
The use of CSF 14-3-3 in the diagnosis of CJD
T h e development of an early reliable and reproducible clinical test for C J D is a high priority for the surveillance of CJD and for obtaining timely data to predict the total numbers of vCJD cases using prediction models. Recently, there has been much interest in the use of quinacrine and chlorpromazine [21] in the treatment of vCJD and this increases the need for early diagnostic markers. It is also important to diagnose CJD early to limit the potential risk of secondary infection by surgical instruments and blood donation.
The use of CSF p I301p I 3 I in the diagnosis of spCJD
In 1986 two proteins, designated p130 and p131, were detected in the cerebrospinal fluid (CSF) of 21 patients with spC J D using two-dimensional electrophoresis [22, 23] . Protein p130 was found to have a molecular mass of 26 kDa and a PI of 5.2, whereas p l 3 1 had a molecular mass of 29 kDa and a PI of 5.1. The use of CSF 14-3-3 in the diagnosis of spCJD
Studies using one-dimensional SDS/PAGE with immunoblotting have shown that the detection of C S F 14-3-3 has a sensitivity of between 90 and 97 yo and specificity of between 87 and 100 (7" for the diagnosis of spCJD [24-281. A total of 329 patients with probable or definite spCJD were investigated in these studies and 93.6'' of these had detectable CSF 14-3-3. Of the 396 patients found not to have spCJD only 26 were found to have detectable CSF 14-3-3. These false positives were caused by conditions associated with acute neuronal loss or damage (Table 1 ). The reason for the high degree of specificity in these initial studies is that they were undertaken as part of organized C J D surveillance systems, and as such the patients investigated were highly selected and many con- ditions that would give rise to a false-positive 14-3-3 were excluded on clinical grounds. T h e high autopsy rate and subsequent neuropathological examination of patients with suspected CJD have confirmed the accuracy of C S F 14-3-3. This has lead the World Health Organization to revise their clinical criteria for the diagnosis of probable spCJD to include a positive 14-3-3 in patients who have a progressive dementia of less than 2 years duration [29] . A recent report has shown that the inclusion of C S F 14-3-3 in the diagnostic criteria has increased the number of cases of spCJD identified [30] . A small percentage of spCJD cases are negative for 14-3-3 and these patients tend to be those with longer disease durations and/or atypical clinical presentations [lo] .
There have been a number of reports of C S F 14-3-3 being detected in conditions such as paraneoplastic syndrome [3 11, transverse myelitis [32] and Hashimoto's encephalitis [33] . Both Hashimoto's encephalitis and paraneoplastic syndrome are conditions that can be difficult to distinguish from spCJD in the early stages. A number of approaches have been used to try to increase the specificity of C S F 14-3-3. Some studies have suggested performing a second lumbar puncture after 1-2 weeks, as many conditions giving a falsepositive C S F 14-3-3 will have undetectable C S F 14-3-3 in the second sample [28] . An alternative approach has been to look at the isoforms of 14-3-3 present in the CSF. Most studies have used a commercially available polyclonal antiserum that detects all isoforms. T h e predominant isoform present in spCJD is y , although smaller amounts of p, E and 17 are also present [34, 35] . There is evidence that 17 is the major isoform present in non-CJD dementia [35] . Thus the development of commercially available isoform-specific antisera that can be used to identify the 14-3-3 isoforms present in C S F may help to increase specificity.
Use of 14-3-3 in the diagnosis of variant C J D
As C S F 14-3-3 has been shown to be very useful in the pre-mortem diagnosis of spCJD there has been much interest in whether it has the same value in vCJD. T h e initial results suggested that C S F 14-3-3 might not be as useful in vCJD as in spCJD [16] . A more recent study which involved a larger number of patients showed that CSF 14-3-3 was detected in 5004 of the patients with histologically confirmed vCJD, but was only found in 9 yo of control cases [36] . Therefore CSF .---14-3-3 has a lower sensitivity for the diagnosis of vCJD than for the diagnosis of spCJD, but has a comparable specificity. This means that the detection of 14-3-3 in this group of patients has a high positive predictive value (86 yo), although the failure to detect 14-3-3 cannot be used to exclude the diagnosis of vCJD. There was no difference between those vCJD patients who were positive for C S F 14-3-3 and those who were negative in terms of age at onset of illness, disease duration and the timing of the lumbar puncture [36] . C S F 14-3-3 may be detected in a second C S F sample taken 3-4 weeks after the first. In our experience two out of three vCJD patients who were initially negative for C S F 14-3-3 had detectable levels in subsequent samples. In addition to being present in only half of the vCJD patients investigated, the amount of 14-3-3 present in the C S F is less than that found in spCJD patients (Figure 1 ).
The use of CSF 14-3-3 in the diagnosis of iatrogenic CJD secondary to human growth hormone administration
Human cadaveric pituitary-derived growth hormone (h-GH) was first used to treat hypopituitary dwarfism in 1958 [37] . T h e hormone was manufactured in batches, and each batch used up to 2000 human pituitary glands. T h e hormone was administered by either intramuscular or subcutaneous injection. T h e first reports of C J D occurring in h-GH recipents were published in 1985 [3840] . Since then nearly 140 further cases have been documented, most of which have been in France [41] . These patients usually present with ataxia and visual disorders and dementia develops at a later stage [42] . C S F 14-3-3 is detectable in these patients, although the proportion of patients with detectable levels depends on when the sample was taken. If the C S F sample is taken in the early stages of disease, when ataxia is the main clinical feature, then only 20 "4, of patients will have detectable C S F 14-3-3, but this figure rises to 100 o o in the later stages of disease when dementia becomes the more prominent feature [43] . Interestingly the amount of CSF 14-3-3 detected in these patients using SDS/PAGE and immunoblotting is similar to that in spCJD patients [44] .
Use of CSF 14-3-3 in the diagnosis of familial CJD
T h e sensitivity of C S F 14-3-3 in the detection of familial C J D cases depends on the mutation involved. C S F 14-3-3 was detected in 97 O 0 of codon E200K mutation cases [25, 26, 45, 46] , in 100 "6 of codon V210I mutation cases [46] , in 40°(, of P102L mutation cases 145,461 but in none of the familial fatal insomnia cases investigated [46] .
Alternative methods for CSF 14-3-3 analysis
T h e analysis of CSF 14-3-3 using SDS/PAGE and immunoblotting is subject to a number of analytical and interpretative problems. T h e most serious of these is the difficulty in assay standardization. There is no recognized international standard against which all patient samples can be compared. This means that the detection of low concentrations of C S F 14-3-3, where the Western blot only shows faint bands, can be difficult. The assessment of the significance of these bands is also subjective, as many patients without CJD can also have small amounts of 14-3-3 present in the CSF. This is an important issue as vCJD patients have lower concentrations of CSF 14-3-3 than spCJD patients (Figure 1 ) [36] . T o try to overcome these problems quantitative assays have been developed [47, 48] . Kenney et al. [47] described an ELISA that uses bovine 14-3-3 as a standard and an in-house monoclonal antibody as a capture antibody. Using this assay it was shown that patients with spC J D had significantly raised CSF 14-3-3 concentrations when compared with patients without spCJD (38.1 f 53.0 versus 3.1 & 2.9 ng/ml, P < 0.001 ; Student's t test). However, comparison of the ELISA and Western blot using the same cohort of patients showed that although the ELISA had comparable specificity with the Western blot it had lower sensitivity. An alternative approach has been used by Leuck et al. [47] , who have developed a protein-capture assay that exploits the protein-binding properties of 14-3-3. A chemically synthesized phosphoserine peptide is covalently linked to a microtitre plate and the 14-3-3 present in C S F or standard binds to the peptide with a high affinity. T h e captured 14-3-3 is then detected using a polyclonal antibody. Using this assay it was shown that although the mean C S F 14-3-3 concentration in vCJD patients was significantly raised when compared with that of control patients, the range of concentrations in these two groups of patients showed considerable overlap and this may limit the diagnostic use of the assay. This study also showed that the mean concentration of CSF 14-3-3 in vCJD patients was half that found in spCJD patients.
Conclusions
CSF 14-3-3 is a sensitive and specific test for spCJD, provided that it is used as a diagnostic test in patients who have a high degree of clinical suspicion. It is less sensitive in patients with vCJD but the high specificity means that the detection of CSF 14-3-3 in a patient with suspected vCJD has a high positive predictive value. T h e value of CSF 14-3-3 in GH-related iatrogenic CJD depends on the clinical stage of the disease, being highly sensitive in the latter stages.
